Lifting Weights on Tirzepatide: What a New Nature Medicine Trial Found About Muscle

Venn diagram showing tirzepatide in the overlap of the GLP-1 receptor and GIP receptor circles, labeled "Dual agonist."

Tirzepatide has a well-known upside: large, sustained weight loss. It also has a less-discussed trade-off. Along with fat, people lose some lean tissue, which includes skeletal muscle. That raises a practical question: can lifting weights while on tirzepatide protect what you have? A new randomized trial published in Nature Medicine on November 9, 2026 tests exactly that, and the results are more nuanced than the headlines suggest. Here is what it found, what it did not, and how to read it.

Diagram showing how tirzepatide works as a dual GIP and GLP-1 receptor agonist
How tirzepatide works on GIP and GLP-1 receptors.

The Short Version

  • Adding three supervised resistance workouts a week did not reduce tirzepatide’s weight or fat loss.
  • It cut lean tissue loss by roughly 23% (about 1.1 kg of extra lean tissue preserved over 40 weeks), but did not eliminate it.
  • The biggest difference was strength: people on tirzepatide alone got weaker, while the lifting group got stronger.
  • Both groups saw similar improvements in blood pressure, blood sugar and cholesterol.

Why Muscle Matters on Tirzepatide

Drugs like tirzepatide can produce 15% to 24% body weight loss in trials. Most of that is fat, but earlier studies using DXA body-composition scans have reported that lean soft tissue falls by around 11% to 14% during incretin-based weight loss. Lean soft tissue is not the same as pure muscle, but it is the best routine proxy researchers have. The concern, especially for people in their 50s and beyond, is sarcopenia (age-related muscle loss), weakness, falls and fractures. If you want background on how the drug works, see our explainers on what tirzepatide is used for and whether tirzepatide is a GLP-1.

How the Trial Worked

Researchers in Western Australia ran a 40-week randomized controlled trial of 120 sedentary adults aged 50 to 70, split evenly between men and postmenopausal women. All had overweight or obesity with at least one weight-related health problem, and none had used incretin drugs before. People with diabetes or cardiovascular disease were excluded.

  • Group 1: tirzepatide alone, with weekly injections starting at 2.5 mg and rising as tolerated up to 15 mg.
  • Group 2: tirzepatide plus three supervised one-hour resistance sessions per week, led by accredited exercise physiologists with progressively harder training.

No specific diet plan was imposed, though participants were encouraged to stay hydrated and get adequate protein and fiber. Body composition was tracked with DXA scans every eight weeks. More than 90% of participants finished the trial, and tirzepatide exposure was similar in both groups, with nearly two-thirds reaching the top dose.

What the Researchers Found

Weight and fat loss were unchanged by exercise

Both groups lost about 22 kg over 40 weeks. Fat loss was 17.2 kg for tirzepatide alone and 18 kg with resistance training. Waist circumference and BMI fell by similar amounts. In other words, adding exercise did not undercut the drug’s main effect.

Lean tissue loss was reduced, not erased

The tirzepatide-only group lost about 4.7 kg of lean soft tissue, compared with 3.6 kg in the lifting group. That is a roughly 23% reduction in loss. Arm and leg lean tissue showed the same pattern, with about 3.6 kg lost on the drug alone versus about 2.9 kg with training. Most of the lean tissue decline happened in the first 24 weeks, after which it largely leveled off, although arm and leg lean tissue kept drifting down.

Strength told the bigger story

This was the standout result. People on tirzepatide alone became weaker on all three strength tests. People who lifted got stronger, even though they still lost some lean tissue. The between-group differences ranged from about 9 kg on the bench press to about 13 kg on the lat pulldown, with a similar benefit in knee extension strength. The authors estimate the strength advantage at roughly 20%.

Notably, similar numbers of people in both groups reported feeling weak or lethargic. That suggests many people may not notice a real loss of strength, which is a reason to measure it rather than rely on feel.

Heart and metabolic benefits were the same

Systolic blood pressure dropped by about 15 to 17 mmHg in both groups, with improvements in blood sugar, insulin, HbA1c, total cholesterol and triglycerides. Resistance training did not add a statistically significant extra benefit on these measures.

Side effects were typical and not worsened by lifting

Gastrointestinal symptoms were the most common: about half of participants had nausea, around a third had constipation, diarrhea or indigestion, and just under a quarter vomited. Exercise did not increase adverse events. Six serious adverse events occurred, none judged related to the study treatments. (Nausea is a common topic on its own; see what causes nausea.)

How to Read These Results

A real benefit, but a modest one for muscle mass

Preserving an extra kilogram of lean tissue over 40 weeks is meaningful but not dramatic. The authors estimate the tirzepatide-only group lost about 2.5 kg of skeletal muscle in the arms and legs, versus about 2 kg with training. For the tirzepatide-only group, that is comparable to a decade or more of typical age-related muscle loss.

Not all lean tissue loss is necessarily bad

The researchers caution that DXA’s “lean soft tissue” includes non-fat components of fat tissue and other water-containing tissue, and that carrying less body weight may reasonably shrink muscle somewhat. DXA also cannot separate muscle from other lean tissue as precisely as MRI. This is why the authors emphasize strength and function over simply preserving mass.

The practical takeaway: aim for strength

The paper’s own conclusion is that people using weight-loss medications should focus on increasing strength through resistance training, rather than only trying to prevent muscle shrinkage. That is a more achievable and more meaningful goal for most people.

Tirzepatide research peptide vial
Tirzepatide is a prescription peptide medication.

Limits of the Study

  • Specific population: sedentary adults aged 50 to 70 without diabetes or cardiovascular disease. Results may differ for younger people, athletes, or those with these conditions.
  • Supervised exercise: three one-hour sessions a week led by exercise physiologists is more support than most people get in real life.
  • DXA, not direct muscle measurement: it measures lean soft tissue, not muscle itself.
  • Long-term function unknown: it is not yet clear whether the strength gains translate into fewer falls or better quality of life years later, or what happens when tirzepatide stops.
  • Funding context: the trial was investigator-initiated. Eli Lilly supplied tirzepatide but no other funding, and several authors disclosed relationships with pharmaceutical companies including Lilly.

Why This Matters After You Stop, Too

A separate body of evidence shows weight tends to return after stopping tirzepatide. In the SURMOUNT-4 trial, people who switched to placebo after 36 weeks of treatment regained about 14% of their body weight over the next year, while those who stayed on the drug lost a further 5.5%. The new trial did not test what happens to muscle and strength after treatment ends, though the authors suggest that continuing resistance exercise could help maintain body-composition gains. That idea remains to be proven.

What to Discuss With Your Clinician

  1. Add resistance training early. The trial started it alongside the drug, not after weight was already lost.
  2. Track strength, not just the scale. Simple measures such as how much you can lift or how easily you stand from a chair are worth monitoring.
  3. Prioritize protein and fiber. The study encouraged adequate protein, and eating less overall makes protein intake easier to overlook.
  4. Check in about the plan after treatment. Ask what the exercise and nutrition plan looks like if you reduce or stop the medication.
  5. Be careful with unapproved alternatives. Some people look for muscle-preserving compounds online. Those are experimental, and exercise is the approach with trial evidence behind it.

Frequently Asked Questions

Does lifting weights slow weight loss on tirzepatide?

Not in this trial. Both groups lost about 22 kg over 40 weeks, and fat loss was similar.

Does resistance training stop muscle loss on tirzepatide?

No, but it reduced lean tissue loss by roughly 23% and clearly improved strength.

How much exercise was used?

Three supervised, progressive one-hour resistance sessions per week for 40 weeks.

Does this apply to semaglutide or other weight-loss drugs?

The trial tested tirzepatide only. The logic is likely similar for other incretin-based drugs, but this study did not test them.

Bottom Line

The big message from this new trial is encouraging and practical: lifting weights does not get in the way of tirzepatide’s weight loss, it partly protects lean tissue, and it makes you stronger while the scale drops. The effect on muscle mass is modest, and the longer-term payoff is still unproven. If you take tirzepatide, or you are thinking about it, resistance training is one of the few add-ons with randomized evidence behind it. Browse more in the blog and join the discussion in our GLP research forum.

Disclaimer: This article is for general education and is not medical advice. Tirzepatide is a prescription medication. Talk to a licensed clinician before starting, stopping or changing any treatment or exercise program.


Discover more from Peptide News Forum

Subscribe to get the latest posts sent to your email.

One response to “Lifting Weights on Tirzepatide: What a New Nature Medicine Trial Found About Muscle”

  1. […] resistance training helped limit lean tissue loss and improved strength on tirzepatide; see our breakdown of the trial. Drug candidates aimed at preserving muscle are in […]

Leave a Reply